![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Advertisement for Relenza CMAJ 2000;162:1662 See response from: M.D. Levy Print ads for Relenza (zanamivir) that have appeared in CMAJ recently state clearly that "patients should be advised of the conditional nature of the market authorization for this indication." However, the patient information booklet on influenza published by Glaxo Wellcome does not mention this. If patients should be advised of something, wouldn't the patient information pamphlet be the place to advise them? When I explain to patients my refusal to prescribe it prophylactically they are sceptical because no advisory on the conditional nature of the authorization appears in the patient brochure.
Deena Ages
© 2000 Canadian Medical Association or its licensors |